Rise Therapeutics, LLC

Publicly observed

Rockville, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Rockville	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Rise Therapeutics, LLC	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	N36JMJ1DKWH6	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Recorded events

Grant16 Sept 2026Publicly observed
NIH SBIR/STTR award: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors
USD 740,140.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease
USD 1,042,478.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Grant16 Sept 2024Publicly observed
NIH SBIR/STTR award: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
USD 811,362.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Grant16 Sept 2024Publicly observed
NIH SBIR/STTR award: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
USD 704,565.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Grant4 Sept 2023Publicly observed
NIH SBIR/STTR award: A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
USD 967,715.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Grant4 Sept 2023Publicly observed
NIH SBIR/STTR award: A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
USD 952,967.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Grant24 Apr 2023Publicly observed
NIH SBIR/STTR award: A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
USD 827,713.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.